Core Insights - Indivior PLC (NASDAQ:INDV) has achieved significant stock performance, reaching an all-time high following strong earnings and a positive business outlook [1][4] Financial Performance - The company reported a 91% increase in net income, rising to $42 million from $20 million year-on-year, while net revenues grew by 2.3% to $314 million from $307 million [2] - For the first nine months of the year, net income totaled $108 million, a turnaround from a $14 million net loss in the same period last year, although total revenues decreased by nearly 1% to $881 million from $889 million [2] Revenue Guidance - Indivior has raised its full-year revenue growth guidance to between $1.18 billion and $1.22 billion, up from the previous range of $1.03 billion to $1.08 billion [3] - Projected revenues from the Sublocade treatment are now expected to be between $825 million and $845 million, an increase from the earlier target of $765 million to $785 million [4] - The adjusted EBITDA outlook has also been upgraded to a range of $400 million to $420 million, compared to the prior estimate of $275 million to $300 million [4]